These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease. Kuwert T; Lange HW; Langen KJ; Herzog H; Aulich A; Feinendegen LE Psychiatry Res; 1989 Sep; 29(3):361-2. PubMed ID: 2532753 [No Abstract] [Full Text] [Related]
28. [SPECT studies with 99mTc-HMPAO in Huntington's chorea patients]. Botsch H; Oepen G; Deuschl G; Wolff G Rofo; 1987 Dec; 147(6):666-8. PubMed ID: 2827263 [TBL] [Abstract][Full Text] [Related]
29. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Hayden MR; Hewitt J; Stoessl AJ; Clark C; Ammann W; Martin WR Neurology; 1987 Sep; 37(9):1441-7. PubMed ID: 2957611 [TBL] [Abstract][Full Text] [Related]
30. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Berent S; Giordani B; Lehtinen S; Markel D; Penney JB; Buchtel HA; Starosta-Rubinstein S; Hichwa R; Young AB Ann Neurol; 1988 Jun; 23(6):541-6. PubMed ID: 2970247 [TBL] [Abstract][Full Text] [Related]
31. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Künig G; Leenders KL; Sanchez-Pernaute R; Antonini A; Vontobel P; Verhagen A; Günther I Ann Neurol; 2000 May; 47(5):644-8. PubMed ID: 10805336 [TBL] [Abstract][Full Text] [Related]
32. How reliable is Ciarmiello A Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2180-2182. PubMed ID: 27511187 [No Abstract] [Full Text] [Related]
33. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Holthoff VA; Koeppe RA; Frey KA; Penney JB; Markel DS; Kuhl DE; Young AB Ann Neurol; 1993 Jul; 34(1):76-81. PubMed ID: 8390806 [TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT: an unexpected case of Huntington's disease. Michels S; Buchholz HG; Rosar F; Heinrich I; Hoffmann MA; Schweiger S; Tüscher O; Schreckenberger M BMC Neurol; 2019 May; 19(1):78. PubMed ID: 31043171 [TBL] [Abstract][Full Text] [Related]
35. Neuropathologic correlation of computerized tomography in Huntington's disease. Terrence CF; Rao G South Med J; 1980 Jun; 73(6):817-8. PubMed ID: 6446759 [TBL] [Abstract][Full Text] [Related]
36. Subcortical structures in aphasia. An analysis based on (F-18)-fluorodeoxyglucose, positron emission tomography, and computed tomography. Metter EJ; Riege WH; Hanson WR; Jackson CA; Kempler D; van Lancker D Arch Neurol; 1988 Nov; 45(11):1229-34. PubMed ID: 3263849 [TBL] [Abstract][Full Text] [Related]
37. Atrophy of caudate nucleus in Huntington's disease measured by computed tomography. Roth J; Havrdová E; Růzicka E J Neurol; 2000 Nov; 247(11):880-1. PubMed ID: 11151423 [No Abstract] [Full Text] [Related]
38. Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease. Garnett ES; Firnau G; Nahmias C; Carbotte R; Bartolucci G J Neurol Sci; 1984 Aug; 65(2):231-7. PubMed ID: 6237177 [TBL] [Abstract][Full Text] [Related]
39. Regional cerebral glucose metabolism differs in adult and rigid juvenile forms of Huntington disease. Matthews PM; Evans AC; Andermann F; Hakim AM Pediatr Neurol; 1989; 5(6):353-6. PubMed ID: 2532511 [TBL] [Abstract][Full Text] [Related]
40. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease. Baxter LR; Mazziotta JC; Pahl JJ; Grafton ST; St George-Hyslop P; Haines JL; Gusella JF; Szuba MP; Selin CE; Guze BH Arch Gen Psychiatry; 1992 Feb; 49(2):148-54. PubMed ID: 1532304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]